All News

cushknees1.jpg

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

d Jack Cush, MD

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article
PSS.hands_.Raynauds.jpg (keep)

Rituximab in Systemic Sclerosis?

d Jack Cush, MD

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article
RheumNow Podcast square

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

d Jack Cush, MD

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article
New podcast up! Download wherever podcasts are available. Upadacitinib Wins in PsA Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers. https://t.co/ZMAUgn10dU https://t.co/QTDqZW3GgG

Links:

Dr. John Cush RheumNow ( View Tweet)
Another study suggests poorer outcomes in Rheum pts on Rituximab. French Cohort study of 1090 inflammatory rheumatic MSK pts -13% w/ severe COVID-19 & 8% who died. 63 RTX pts had more severe disease, longer hosp stays & more death (21% vs 7%) https://t.co/5UCvFeVWRS

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 insight from the Lupus panel--originally tweeted by @KDAO2011 "Lupus panniculitis feels like wood: mummified degenerative fat replaced by fibers " #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Interestng overview/read on the Inflammasome - its history, clinical targeting and new inflammasome (NLRP3) inhibitors in development by pharma. https://t.co/DEdP09GZd7

Links:

Dr. John Cush RheumNow ( View Tweet)

Are you signed up for the RheumNow daily newsletter? Head over to RheumNow and sign up to have the news delivered to your inbox daily. https://t.co/HSBjF6ySNv

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 coverage from @uptoTate "Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! " #RheumNowLive

Dr. John Cush RheumNow ( View Tweet)

News Feature: Upadacitinib Clinical Efficacy in Psoriatic Arthritis https://t.co/gdAnqEFk3n https://t.co/PNYwhRFTEK

Links:

Dr. John Cush RheumNow ( View Tweet)
Thanks @doctorRBC for sharing this from #RNL2021 "Dr. N Haroon talking about SpA treatment -TNFi can reduce spinal radiographic progression -Better to taper biologics in AxSpA than stopping -JAKinibs are coming "

Dr. John Cush RheumNow ( View Tweet)

News Feature: HLA B27 Iritis - RNL 2021 Highlights by Dr. Rachel Tate ( @uptoTate ) #RNL2021 #RheumNow https://t.co/SlftHnhD6z https://t.co/utjOU0rfBP

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Inflammatory Conditions Up the Risk of Premature Myocardial Infarction https://t.co/gbPpAYJGFg https://t.co/ValdJWGyxl

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Aortic Calcification and Lumbar Fracture Risk in Older Men https://t.co/6gcoP9EFey #RheumNow https://t.co/BTTrYAoyNp

Links:

Dr. John Cush RheumNow ( View Tweet)
In the UK, NICE has recommended Kineret (anakinra) for use as 1st line biologic Rx in systemic JIA and adult-onset still’s disease (AOSD); but pts must first fail a DMARD - the latter is unfortunate as systemic Sxs of Still's do not respond to usual DMARDs.https://t.co/BNdqhLy9jg

Links:

Dr. John Cush RheumNow ( View Tweet)

From @doctorRBC #RNL2021 coverage "Avoid the lawsuit... “warty” appearing skin lesions in a lupus can be confused as skin cancer on shave biopsy when in fact it could be VERRUCOUS LUPUS which can be treated with HCQ. Perform a deeper biopsy. - Dr. Clay Cockrell " #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Comparison of oral and parenteral MTX shows oral MTX in RA is non inferior to subcutaneous MTX treatment (in 640 RA pts) with regard to disease activity, but oral MTX had fewer adverse events than SC ( 41% vs 52%, p= 0.005). https://t.co/828kcG53iz

Links:

Dr. John Cush RheumNow ( View Tweet)

Matched cohort Nurses’ Health Study looked at 283 pre‐RA pts (mean 9.7 years before RA Dx) and and 842 controls; 21% pre‐RA were ACPA+. ACPA+ was associated with increased risk of COPD (HR 3.04) that was not seen in ACPA- pts. https://t.co/HNB11eAiva

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Olga Petryna ( @drpetryna) weighing the future Rx in RA by Dr. Fleischmann: -CD22, new IL6i & GM-CSF show promises but far form being available -bDMARD or tsDMARD after MTX but work better wMTX -JAKS better choice for mono-therapy but safety is a concern #RNL2021

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 coverage from @doctorRBC ACR’s conditional recommendations for tx of specific RA populations #RheumNow https://t.co/3uo9x42bPX
Dr. John Cush RheumNow ( View Tweet)
×